Stock Analiz

Organigram Global Inc. OGI

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$0.83Market cap $117M
Open the interactive analysis →

Organigram Global Inc. (OGI) is a healthcare company listed in the US with a market value of about $117M. In the twelve months to June 30, 2026 it had revenue of $217M and net income of $61M, a net margin of 28.0%.

Its overall Stock Analiz score is 2.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is track record (1/5).

Key numbers: a P/E of 1.9, 5-year revenue growth of 65% a year, a 5-year average ROIC of -14%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 203% above the current price.

About Organigram Global

Organigram Global is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $10M in 2018 to $182M in 2025, growth of about 52.3% a year. It was profitable in 1 of the last 7 years in our data. Its share count fell by 9% over three years (buybacks).

Score: 2.2 / 5

Value3/5
Future growth4/5
Track record1/5
Financial health2/5
Shareholder returns1/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • Price below intrinsic value (DCF, moderate assumptions)
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year

Checks not passed

  • P/FCF below 20
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%
  • Profitable 5 years in a row
  • ROE above 15%
  • Positive free cash flow

Valuation

P/E (TTM)1.9
Forward P/E34.5
P/FCF—
P/S0.5
P/B0.3
EV/EBITDA11.4
PEG—
Dividend yield0.00%
FCF yield-17.8%
Shareholder yield0.0%
Intrinsic value vs. price+203%

Growth and quality

Revenue growth (1 yr)6.3%
Revenue growth (5 yrs, per year)65.5%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-74.4%
ROIC (5-yr avg.)-14.1%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420222021202020192018
Revenue$217M$182M$118M$111M$63M$66M$61M$10M
Net income$61M-$17M-$34M-$11M-$104M-$104M-$7M$16M
Free cash flow-$21M-$17M-$635543-$65M-$32M-$94M-$108M-$53M
EPS (diluted)$0.44$-0.14$-0.24$-0.08$-0.74$-0.74$-0.05$0.11
Net margin28.0%-9.6%-28.4%-9.8%-165.1%-156.9%-11.9%165.0%
ROIC——-11.7%-8.4%-19.1%-32.6%1.1%15.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Organigram Global’s P/E ratio?

About 1.9, based on the last twelve months of diluted earnings per share (forward P/E about 34.5).

Is Organigram Global stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 203% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Organigram Global pay a dividend?

Not currently.

Is Organigram Global a good stock to buy?

We do not give buy or sell advice. Organigram Global scores 2.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.